Successful challenge of voriconazole in a patient with posaconazole-associated minor drug eruption: A case report.

Journal of Clinical Pharmacy and Therapeutics
Benjabhorn WeeraphonSang Usayaporn

Abstract

Triazole antifungal-associated skin rash is rare. Data on cross-reaction triazole antifungals remain inconclusive and poorly defined. We report successful voriconazole challenge in a patient allergic to posaconazole. A 38-year-old female diagnosed with acute myeloid leukaemia and receiving chemotherapy treatment in our institution developed a maculopapular rash after receiving oral posaconazole for invasive fungal infection prophylaxis. Other potential causes that may have attributed to this response, such as other drugs that the patient was taking and infections, were excluded. Voriconazole, another triazole antifungal, was successfully substituted for posaconazole. This is the first case report of a patient, with a history of posaconazole allergy, successfully challenged with voriconazole.

References

Jan 24, 2009·Antimicrobial Agents and Chemotherapy·Angie Pinto, Raymond C Chan
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of America
Nov 28, 2015·The Journal of Antimicrobial Chemotherapy·Oliver A CornelyHetty Waskin
Mar 24, 2016·JAMA Dermatology·Audrey A JacobsenJohn Strasswimmer
Jul 20, 2016·Journal of Clinical Pharmacy and Therapeutics·D Benjamin LashA Heidari
Oct 21, 2015·Pharmacy : Journal of Pharmacy, Education and Practice·Simon LeungJade Machin
Aug 8, 2018·The Journal of Antimicrobial Chemotherapy·Johan A MaertensUNKNOWN European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplant
Sep 21, 2019·Recent Patents on Inflammation & Allergy Drug Discovery·Gianfranco CalogiuriCaterina Foti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.